ClinicalTrials.gg
Status unknownNCT03265457Updated Jun 26, 2018

The Endothelial Count in Pxf

An observational study in Pseudoexfoliation Syndrome, sponsored by Assiut University. Status unknown. Per ClinicalTrials.gov, last updated 2018-06-26.

Sponsored by Assiut University · Observational

The sponsor has not verified this record recently (last verified Jun 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
20
Sex
All
01

Study summary

Pseudoexfoliation Syndrome Is a common disorder in Egypt. IT is one of the common causes of coexisting cataract and glaucoma. It may be associated with a less than normal endothelial count.

Read the detailed description

The corneal Endothelium is essential for the maintenance of normal corneal hydration, thickness, and transparency.

In patients with pseudoexfoliation syndrome , quantitative and qualitative morphological changes of the corneal endothelium have been demonstrated in specular and electron microscopic studies.

Specular microscopy is a non-invasive technique to access the structure and function of the corneal endothelium.

Our research question is to study Endothelial cell count in patients with pseudoexfoliation syndrome \& compare it to age matched group.

02

Conditions studied

  • Pseudoexfoliation Syndrome

Browse trials for

03

In context

Exfoliation Syndrome

72 studies on the registry are indexed under Exfoliation Syndrome; 20 are open to participants now.

This study's planned enrollment of 20 is below the median of 76 across 38 observational studies indexed under Exfoliation Syndrome.

Browse Exfoliation Syndrome studies →

Lead sponsor

Assiut University is the lead sponsor of 5,079 studies on the registry; 2,177 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with pseudoexfoliation syndrome

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with pseudoexfoliation syndrome

Exclusion criteria

Exclusion Criteria:

  • Patients with previous intra ocular surgeries.
  • Patients with uveitis
  • Patients with fuck's endothelial dystrophy
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • patient with pseudoexfoliation syndrome

    The corneal Endothelial cell count will be measured by specular microscopy

    Other: Specular microscopy

  • Normal people at same age

    Other: Specular microscopy

Interventions

  • OtherSpecular microscopy

    Comparison between corneal Endothelial count in patients with pseudoexfoliation syndrome and age matched group

06

What researchers measure

Primary outcomes

  1. Comparison between endothelial cell count in patients with Pseudoexfoliation syndrome and age matched controls.

    The corneal Endothelial cell count in patients with pseudoexfoliation syndrome will be measured by the specular microscopy \& compared with the normal endothelial count in people at the same group

    Time frame: One year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Miyake K, Matsuda M, Inaba M. Corneal endothelial changes in pseudoexfoliation syndrome. Am J Ophthalmol. 1989 Jul 15;108(1):49-52. doi: 10.1016/s0002-9394(14)73259-3. PubMed 2750833 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2018; primary completion for Oct 2019, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2017
First posted
Aug 29, 2017
StartEst.
Oct 1, 2018
Primary completionEst.
Oct 1, 2019
CompletionEst.
Oct 1, 2020
Last update
Jun 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03265457
Lead sponsor
Assiut University
Responsible party
Amira Asem (Principal investigator, Assiut University) — Principal investigator
First posted
Aug 29, 2017
Start date
Oct 1, 2018 (estimated)
Primary completion
Oct 1, 2019 (estimated)
Completion
Oct 1, 2020 (estimated)
Last update
Jun 26, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion